Biomarkers for Alzheimer's Disease Progression
AssigneeNovartis AG
InventorJonathan Benjamin Singer
Life of this patent
Estimating the term…
Abstract
This invention relates generally to the analytical testing of tissue samples in vitro, and more particularly to aspects of genetic polymorphisms associated with the conversion from Mile Cognitive Impairment to dementia, e.g., Alzheimer's Disease (AD). The invention provides AD-associated mutations which are useful in the diagnosis, prognosis or therapeutic treatment of dementia, e.g., Alzheimer's Disease.
Claims13
Use of rivastigmine (Exelon) in the manufacture of a medicament for the treatment of Alzheimer's Disease with a reduced toxicity or increased effect in a selected subject population, wherein the subject population is selected on the basis of the presence of at least one gene mutation selected from the group consisting of:
- MUT-1;
- MUT-2;
- MUT-3;
- MUT-4;
- MUT-5;
- MUT-6;
- MUT-7;
- MUT-8;
- MUT-9;
- MUT-10;
- MUT-11;
- MUT-12;
- MUT-13;
- MUT-14;
- MUT-15;
- MUT-16;
- MUT-17;
- MUT-18;
- MUT-19;
- MUT-20;
- MUT-21;
- MUT-22;
- MUT-23;
- MUT-24;
- MUT-25.
A method for treating Alzheimer's Disease in a subject, comprising the steps of:
- (a) obtaining the genotype or haplotype of the subject at a genetic locus or loci of at least one gene selected from the group consisting of:
- AK5;
- BAI3;
- BBX;
- C18orf20;
- C5orf3;
- CACNA2D1;
- CCDC2;
- CD47;
- CNTNAP5;
- GRIA1;
- LAMA3;
- LOC131368;
- LRRC19;
- MGC27434;
- NFKBIZ;
- PIK3C3;
- SLC1A3;
- SPAG16;
- ST3GAL3;
- TEK;
- and TNFSF11, wherein the genotype and/or haplotype is indicative of a propensity for having Alzheimer's Disease;
- and
- (b) administering an anti-Alzheimer's Disease therapy to the subject.
A method for identifying a subject with a disorder for which an Alzheimer's Disease-associated mutation identified in TABLE 1 is predictive, comprising the steps of:
- (a) obtaining the genotype or haplotype of the subject at a genetic locus or loci of at least one gene selected from the group consisting of:
- AK5;
- BAI3;
- BBX;
- C18orf20;
- C5orf3;
- CACNA2D1;
- CCDC2;
- CD47;
- CNTNAP5;
- GRIA1;
- LAMA3;
- LOC131368;
- LRRC19;
- MGC27434;
- NFKBIZ;
- PIK3C3;
- SLC1A3;
- SPAG16;
- ST3GAL3;
- TEK;
- and TNFSF11;
- (b) assessing the genotype and/or haplotype to determine the presence of a mutation or polymorphism selected from the group consisting of:
- MUT-1;
- MUT-2;
- MUT-3;
- MUT-4;
- MUT-5;
- MUT-6;
- MUT-7;
- MUT-8;
- MUT-9;
- MUT-10;
- MUT-11;
- MUT-12;
- MUT-13;
- MUT-14;
- MUT-15;
- MUT-16;
- MUT-17;
- MUT-18;
- MUT-19;
- MUT-20;
- MUT-21;
- MUT-22;
- MUT-23;
- MUT-24;
- and MUT-25, wherein the presence of the mutation or polymorphism is indicative of a propensity of the subject to have a disorder for which the Alzheimer's Disease-associated mutation identified in TABLE 1 is predictive;
- and
- (c) identifying the subject as having a propensity for having a disorder for which an Alzheimer's Disease-associated mutation identified in TABLE 1 is predictive.
A method for determining, prior to initiation of treatment, whether a subject should be included in a study of a therapeutic or study agent;
- comprising:
- (a) interrogating the genotype and/or haplotype of the subject at a genetic locus or loci of at least one gene selected from the group consisting of:
- AK5;
- BAI3;
- BBX;
- C18orf20;
- C5orf3;
- CACNA2D1;
- CCDC2;
- CD47;
- CNTNAP5;
- GRIA1;
- LAMA3;
- LOC131368;
- LRRC19;
- MGC27434;
- NFKBIZ;
- PIK3C3;
- SLC1A3;
- SPAG16;
- ST3GAL3;
- TEK;
- and TNFSF11;
- (b) then:
- including the subject in the study if the genotype is indicative of a propensity to Alzheimer's Disease by the subject;
- (ii) excluding the subject from the study if the genotype is not indicative of a propensity to Alzheimer's Disease by the subject;
- or
- (iii) both (i) and (ii).
A method for determining the responsiveness of a subject with a disorder to treatment, comprising the steps of:
- (a) obtaining the genotype or haplotype of the subject at a genetic locus or loci of at least one gene selected from the group consisting of:
- AK5;
- BAI3;
- BBX;
- C18orf20;
- C5orf3;
- CACNA2D1;
- CCDC2;
- CD47;
- CNTNAP5;
- GRIM;
- LAMA3;
- LOC131368;
- LRRC19;
- MGC27434;
- NFKBIZ;
- PIK3C3;
- SLC1A3;
- SPAG16;
- ST3GAL3;
- TEK;
- and TNFSF11;
- (b) assessing the genotype and/or haplotype to determine the presence of a mutation or polymorphism selected from the group consisting of:
- MUT-1;
- MUT-2;
- MUT-3;
- MUT-4;
- MUT-5;
- MUT-6;
- MUT-7;
- MUT-8;
- MUT-9;
- MUT-10;
- MUT-11;
- MUT-12;
- MUT-13;
- MUT-14;
- MUT-15;
- MUT-16;
- MUT-17;
- MUT-18;
- MUT-19;
- MUT-20;
- MUT-21;
- MUT-22;
- MUT-23;
- MUT-24;
- and MUT-25, wherein the presence of the mutation or polymorphism is indicative of a subject that is responsive to treatment of the disorder;
- and
- (c) identifying the subject as responsive to treatment of the disorder.
A method for determining, prior to treatment, a subject that will develop toxicity when treated with a compound;
- comprising:
- (a) obtaining the genotype or haplotype of the subject at a genetic locus or loci of at least one gene selected from the group consisting of:
- AK5;
- BAI3;
- BBX;
- C18orf20;
- C5orf3;
- CACNA2D1;
- CCDC2;
- CD47;
- CNTNAP5;
- GRIA1;
- LAMA3;
- LOC131368;
- LRRC19;
- MGC27434;
- NFKBIZ;
- PIK3C3;
- SLC1A3;
- SPAG16;
- ST3GAL3;
- TEK;
- and TNFSF11;
- (b) assessing the genotype and/or haplotype to determine the presence of a mutation or polymorphism selected from the group consisting of:
- MUT-1;
- MUT-2;
- MUT-3;
- MUT-4;
- MUT-5;
- MUT-6;
- MUT-7;
- MUT-8;
- MUT-9;
- MUT-10;
- MUT-11;
- MUT-12;
- MUT-13;
- MUT-14;
- MUT-15;
- MUT-16;
- MUT-17;
- MUT-18;
- MUT-19;
- MUT-20;
- MUT-21;
- MUT-22;
- MUT-23;
- MUT-24;
- and MUT-25, wherein the presence of the mutation or polymorphism is indicative of a subject that will develop toxicity when treated with the compound;
- and
- (c) identifying the subject as a subject that will develop toxicity when treated with the compound.
A method for monitoring the progression or development of toxicity in a subject being treated with a compound, the method comprising:
- (a) providing a first test biological sample from the subject;
- (b) providing a second test biological sample from the subject which is later in time than the first test biological sample;
- (c) contacting the test biological samples with a reagent for detecting a polynucleotide or polypeptide encoded by a gene having a sequence comprising a mutation selected from the group consisting of:
- MUT-1;
- MUT-2;
- MUT-3;
- MUT-4;
- MUT-5;
- MUT-6;
- MUT-7;
- MUT-8;
- MUT-9;
- MUT-10;
- MUT-11;
- MUT-12;
- MUT-13;
- MUT-14;
- MUT-15;
- MUT-16;
- MUT-17;
- MUT-18;
- MUT-19;
- MUT-20;
- MUT-21;
- MUT-22;
- MUT-23;
- MUT-24;
- and MUT-25;
- (d) determining the level of expression of the polypeptide or polynucleotide in the test biological samples;
- and
- (e) comparing the level of the polynucleotide or polypeptide level in the first test biological sample with the level of the polynucleotide or polypeptide in the second test biological sample, wherein an increase or a decrease in the level of polynucleotide or polypeptide in the second test biological sample relative to the level of the polynucleotide or polypeptide in the first test biological sample indicates the progression or development of toxicity in the subject being treated with the compound.
A method for determination of when treatment with a compound should be discontinued in a subject at risk of having, toxicity during or after treatment with the compound, comprising the steps of:
- (a) providing a test biological sample;
- (b) contacting the test biological sample with a reagent for detecting a polynucleotide or polypeptide encoded by a gene having a sequence comprising a mutation selected from the group consisting of:
- MUT-1;
- MUT-2;
- MUT-3;
- MUT-4;
- MUT-5;
- MUT-6;
- MUT-7;
- MUT-8;
- MUT-9;
- MUT-10;
- MUT-11;
- MUT-12;
- MUT-13;
- MUT-14;
- MUT-15;
- MUT-16;
- MUT-17;
- MUT-18;
- MUT-19;
- MUT-20;
- MUT-21;
- MUT-22;
- MUT-23;
- MUT-24;
- and MUT-25,
- (c) determining the level of expression of the polypeptide or polynucleotide in the test biological sample;
- and
- (d) comparing the level of the polynucleotide or polypeptide level in the test biological sample with the level of the polynucleotide or polypeptide in a standard reference sample, wherein similarity between the level of polynucleotide or polypeptide and the level of the polynucleotide or polypeptide in the standard reference sample is indicative of the development of toxicity in the subject and determines that the compound should be discontinued.
Dependencies are inferred from the claim text.